Evidence map›Paper›PMID 33441125›Full record

ArticleBMC complementary medicine and therapies2021

Protective effect of 6-paradol in acetic acid-induced ulcerative colitis in rats.

Misbahuddin Rafeeq, Hussam Aly Sayed Murad, Hossam Mohammed Abdallah, Ali M El-Halawany

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in BMC complementary medicine and therapies, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 37 citations in OpenAlex.

  1. Chemical Profiling ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Frontiers in pharmacology · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Therapeutic EvaluationPharmaceutics · 2025
    Article
  9. Collagen Peptides andFood science & nutrition · 2025
    Article
  10. Review
  11. Article
  12. A critical review of Ginger's (Frontiers in nutrition · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Misbahuddin RafeeqDepartment of Pharmacology, Faculty of Medicine, King Abdulaziz University (KAU), Rabigh Campus, Jeddah, 21589, Saudi Arabia. marafeeq@kau.edu.sa.ORCID http://orcid.org/0000-0002-7219-9149
Hussam Aly Sayed MuradDepartment of Pharmacology, Faculty of Medicine, King Abdulaziz University (KAU), Rabigh Campus, Jeddah, 21589, Saudi Arabia.
Hossam Mohammed AbdallahDepartment of Natural Products and Alternative Medicine, Faculty of Pharmacy, KAU, Jeddah, 21589, Saudi Arabia.
Ali M El-HalawanyDepartment of Natural Products and Alternative Medicine, Faculty of Pharmacy, KAU, Jeddah, 21589, Saudi Arabia.
Cairo University · EGAin Shams University · EGKing Abdulaziz University · SA

Funding

Deanship of Scientific Research, King Abdulaziz University (SA) G-128-828-1438
6 · The paper itself

Abstract

backgroundUlcerative colitis is a gut inflammatory disorder due to altered immune response to gut microbiome, with interplay of environmental and genetic factors. TNF-α activates inflammatory response through a cascade of immune responses, augmenting pro-inflammatory mediators and proteases, activating chemotaxis, and infiltration of inflammatory cells, leading to ulceration and haemorrhage through cytotoxic reactive oxygen species. 6-Paradol, a dietary component in several plants belonging to the Zingiberaceae family, has shown anti-inflammatory and antioxidant activities. Current study evaluates the effect of 6-paradol in amelioration of ulcerative colitis in rats for the first time.

methods6-Paradol (95% purity) was obtained from seeds of Aframomum melegueta. Rats were divided randomly into six groups (n = 8). Group one was administered normal saline; group two was treated with the vehicle only; group three, sulfasalazine 500 mg/kg; and groups four, five, and six, were given 6-paradol (50, 100, 200, respectively) mg/kg orally through gastric gavage for 7 days. Colitis was induced on 4th day by intrarectal administration of 2 ml acetic acid (3%), approximately 3 cm from anal verge. On 8th day, rats were sacrificed, and distal one-third of the colon extending proximally up to 4 cm from anal orifice was taken for biochemical and gross examination. Two centimetres of injured mucosal portion was taken for histopathological investigations. SPSS (ver.26) was used for statistical analysis.

resultsColonic and serum glutathione (GSH) levels decreased, while colonic and serum malondialdehyde (MDA), colonic myeloperoxidase (MPO) activity, serum interleukin-6 (IL-6), serum tumour necrosis factor-α (TNF-α) levels, and colon weight to length ratio were increased significantly in the colitis untreated group compared to normal control. Treatment with 6-paradol considerably improved all these parameters, especially at a dose of 200 mg/kg (p < 0.001), revealing non-significant differences with sulfasalazine 500 mg/kg and normal control (p = 0.998). Sulfasalazine and 6-paradol in a dose dependent manner also markedly reversed mucosal oedema, atrophy and inflammation, cryptic damage, haemorrhage, and ulceration. There were non-significant differences between low and medium doses and between medium and high doses of 6-paradol for IL-6 and serum MDA levels.

conclusion6-Paradol demonstrated protection against acetic acid-induced ulcerative colitis, probably by anti-inflammatory and antioxidant actions.

Indexed as

Colitis, UlcerativeAcetic AcidAnimalsAnti-Inflammatory AgentsAntioxidantsColonGlutathioneGuaiacolKetonesMaleRatsRats, Sprague-DawleySeedsZingiberaceae6-paradolAcetic AcidAnti-Inflammatory AgentsAntioxidantsGlutathioneGuaiacolKetones6-paradolAntioxidantGingerGrain of paradiseGutIBDSpices

Identifiers

PMID33441125
PMCPMC7805070
OpenAlexW3119807802

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.